Atypical Antipsychotic

Schizophrenia

<section class="Section" data-sectioncode="34089-3"><a name="LINK_88ed48cc-536d-494e-bcc6-0bf5935ec7c1"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">CAPLYTA capsules contains lumateperone, an atypical antipsychotic, present as lumateperone tosylate salt with the chemical name 4-((6b<span class="Italics">R</span>,10a<span class="Italics">S</span>)-3-methyl-2,3,6b,9,10,10<span class="Italics">a</span>-hexahydro-1<span class="Italics">H</span>,7<span class="Italics">H</span>-pyrido[3',4':4,5]pyrrolo[1,2,3-<span class="Italics">de</span>]quinoxalin-8-yl)-1-(4-fluoro-phenyl)-butan-1-one 4-methylbenzenesulfonate. Its molecular formula is C<span class="Sub">31</span>H<span class="Sub">36</span>FN<span class="Sub">3</span>O<span class="Sub">4</span>S, and its molecular weight is 565.71 g/mol with the following structure:</p><div class="Figure"><img alt="Chemical Structure" src="caplyta-1.jpg"/></div><p>CAPLYTA capsules are intended for oral administration. Each CAPLYTA capsule contains lumateperone and are available in 42 mg (equivalent to 60 mg of lumateperone tosylate), 21 mg (equivalent to 30 mg of lumateperone tosylate), and 10.5 mg (equivalent to 15 mg of lumateperone tosylate) strengths. Capsules include the following inactive ingredients: croscarmellose sodium, gelatin, magnesium stearate, mannitol, and talc. Colorants include FD&amp;C blue #1 and red #3 (42 mg), FDA/E172 black iron oxide, FDA/E172 red iron oxide and FD&amp;C red #3 (10.5 mg), and titanium dioxide (42 mg, 21 mg and 10.5 mg). </p></section>

CAPLYTA

lumateperone

lumateperone 42 MG Oral Capsule

Caplyta

lumateperone 42 MG Oral Capsule [Caplyta]

lumateperone 10.5 MG Oral Capsule

lumateperone 10.5 MG Oral Capsule [Caplyta]

lumateperone 21 MG Oral Capsule

lumateperone 21 MG Oral Capsule [Caplyta]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Pharmacy List 

Online Sample Form 

Formulary Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Prior Authorization Submission Information

Pharmacy Callback Guide 

Enroll in Patient Savings Program 

Free 15-Day Voucher 

Other HCP Resources (Videos): Biploar Depression

About Caplyta: Biploar Depression

Side Effects: Biploar Depression

Taking Caplyta: Biploar Depression

Patient Stories: Biploar Depression

Patient Resources: Biploar Depression

Patient Brochure: Biploar Depression

Doctor Discussion Guide: Biploar Depression

Mood Disorder Questionnaire: Biploar Depression

Caplyta Savings Card Reimbursement Form

Instructions For Use: Biploar Depression

Other HCP Resources: Schizophrenia

About Caplyta: Schizophrenia

Side Effects: Schizophrenia

Taking Caplyta: Schizophrenia

FAQs: Schizophrenia

Patient Resources: Schizophrenia

Doctor Discussion Guide: Schizophrenia

Patient Brochure (English): Schizophrenia

Patient Brochure (Spanish): Schizophrenia

Instructions For Use: Schizophrenia